Knockdown of miR-182 changes the sensitivity of triple-negative breast cancer cells to cisplatin

Basit Öğe Kaydı
dc.authoriddonmez, hulya/0000-0003-3288-0690
dc.contributor.authorDonmez, Hulya
dc.contributor.authorBatar, Bahadir
dc.contributor.authorTurgut, Burhan
dc.date.accessioned2025-04-06T12:23:51Z
dc.date.available2025-04-06T12:23:51Z
dc.date.issued2025
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractBreast cancer is the most common malignancy that affects women. MicroRNAs (miRNAs) play an essential role in cancer therapy and regulate many biological processes such as cisplatin resistance. The study's objective was to determine whether miR-182 dysregulation was the cause of cisplatin resistance in TNBC cell line MDA-MB-231. To determine the expression of miR-182, PCR was performed with primers specific to miR-182, and agarose gel electrophoresis was performed. To reduce the expression of miR-182 in MDA-MB-231 cells, anti-miR-182 oligonucleotides were used. RT-qPCR was used to confirm knockdown. The knockdown and control groups were treated with cisplatin at the same time. Propidium iodide (PI) and Annexin V staining were performed for apoptosis assay. Flow cytometric analysis was used to investigate the effect of miR-182 knockdown on cell cycle arrest. In comparison to untreated control MDA-MB-231 cells with MDA-MB-231 cells treated with anti-miR-182, there was a significant increase in the cisplatin-induced early apoptosis phase (p = 0.023). Also, inhibition of miR-182 significantly increased the cell cycle arrest at the G2/M phase in MDA-MB-231 cells (p = 0.031). Our results revealed that miR-182 inhibition may play a role in the overcoming of cisplatin resistance by inducing apoptosis and, cell cycle arrest in TNBC.
dc.identifier.doi10.1080/15257770.2025.2451818
dc.identifier.issn1525-7770
dc.identifier.issn1532-2335
dc.identifier.pmid39797947
dc.identifier.scopus2-s2.0-85214653356
dc.identifier.scopusqualityQ4
dc.identifier.urihttps://doi.org/10.1080/15257770.2025.2451818
dc.identifier.urihttps://hdl.handle.net/20.500.11776/17202
dc.identifier.wosWOS:001394808900001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Inc
dc.relation.ispartofNucleosides Nucleotides & Nucleic Acids
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250406
dc.subjectApoptosis
dc.subjectbreast cancer
dc.subjectcell cycle
dc.subjectcisplatin resistance
dc.subjectmiR-182
dc.titleKnockdown of miR-182 changes the sensitivity of triple-negative breast cancer cells to cisplatin
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu